Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 117	$ 112	$ 383
License to domvanalimab
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	0	0	329
License and R&D services
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	79	74	1
Access rights
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	33	33	31
License to domvanalimab
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	0	0	15
R&D services
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	5	0	0
Access rights
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 0	$ 5	$ 7